Samsung Epis Holdings Co., Ltd. announced its establishment as a new investment holding company following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics. The holding company will be listed on Korea Exchange (KRX) on November 24, 2025, after establishing a new subsidiary company on November 14, 2025.
Kyung-Ah Kim will serve as President and Chief Executive Officer of Samsung Epis Holdings while maintaining her current role as President and CEO of Samsung Bioepis. "The new investment holding company will focus on discovering and securing investment opportunities in biotechnology for the company and its subsidiaries' long-term growth, with scientific innovation remaining the source of our value creation," Kim stated.
Strategic Focus on Next-Generation Technologies
Samsung Epis Holdings will operate as an investment holdings company dedicated to biopharmaceuticals and biotechnology, optimizing business strategies for its subsidiaries and maximizing corporate and shareholder value through proactive R&D and investment. The company will implement a focused growth strategy designed to ensure efficient resource allocation while reinforcing business strategies and platforms for its two subsidiaries.
The new subsidiary company under Samsung Epis Holdings will develop next-generation biotechnology platforms targeting various modalities to identify future growth engines beyond the biosimilar business. This subsidiary will focus on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies.
Samsung Bioepis Performance and Expansion Plans
Samsung Bioepis will continue operating its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings. Since its foundation in 2012, Samsung Bioepis has developed the industry's most rapidly advancing biosimilar medicines portfolio, with 11 biosimilars approved and available around the world.
In 2024, Samsung Bioepis achieved record-breaking sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. The company will focus on strengthening its development capabilities, with a goal of securing 20+ biosimilars in the long-term.
Samsung Bioepis has opened access to biologic medicines across immunology, oncology, ophthalmology, hematology, and nephrology, and is expanding into other therapeutic areas to address unmet patient needs. The company will remain committed to ensuring the continued development, manufacturing, and distribution of quality-assured biosimilar medicines to patients worldwide.
Independent Decision-Making Structure
Kim emphasized the strategic benefits of the new structure: "By establishing an independent decision-making structure, we see the potential for further growth and investment. Progress is being made to secure next-generation therapeutic technology on the back of the capabilities accumulated through our biosimilar business. With the spin-off, we expect to have more opportunities to explore next-generation growth drivers."
The restructuring positions Samsung Epis Holdings to leverage its established biosimilar expertise while expanding into emerging biotechnology platforms and drug discovery initiatives through strategic partnerships with global pharmaceutical companies.
